<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872832</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA3170-104</org_study_id>
    <nct_id>NCT01872832</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Study in Japanese Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RDEA3170 in Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the safety, tolerability, and serum uric acid lowering effect of&#xD;
      RDEA3170 in healthy Japanese males to allow comparison with the Western population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While clinical studies of RDEA3170 to date have been limited to a Western population, it is&#xD;
      recognized that both intrinsic and extrinsic factors may impact the PK, PD, safety, and dose&#xD;
      response in different ethnic populations. The purpose of this study is to explore the safety,&#xD;
      tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of single and multiple doses of&#xD;
      RDEA3170 in healthy Japanese males, and to allow comparison of these parameters with the&#xD;
      Western population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters</measure>
    <time_frame>5 to 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK profile of RDEA3170 from plasma and urine</measure>
    <time_frame>Day 1 through 15</time_frame>
    <description>Profile in terms of AUC, Tmax, Cmax, and t1/2&#xD;
AUC: area under the plasma concentration versus time curve; Tmax: time to maximum plasma concentration; Cmax: maximum plasma drug concentration; t1/2: apparent terminal half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD profile of RDEA3170 from serum and urine</measure>
    <time_frame>Day 1 through 15</time_frame>
    <description>Profile in terms of sUA concentration; CLr; urine uric acid excretion amount; fractional excretion of uric acid&#xD;
sUA: serume urate; CLr: renal clearance</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>5 mg RDEA3170</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 5 mg or placebo fasted and fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg RDEA3170</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 10 mg or placebo fasted and fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg RDEA3170</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 15 mg or placebo fasted and fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5 mg RDEA3170</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 2.5 mg or placebo fasted and fed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170 and Placebo</intervention_name>
    <arm_group_label>10 mg RDEA3170</arm_group_label>
    <arm_group_label>15 mg RDEA3170</arm_group_label>
    <arm_group_label>2.5 mg RDEA3170</arm_group_label>
    <arm_group_label>5 mg RDEA3170</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand the study procedures and the risks involved, and willing to provide&#xD;
             written informed consent before the first study related activity.&#xD;
&#xD;
          -  Healthy adult male subject born in Japan.&#xD;
&#xD;
          -  Subject has parents and grandparents who are Japanese.&#xD;
&#xD;
          -  Subject is in possession of a valid Japanese passport.&#xD;
&#xD;
          -  All laboratory parameters should be within normal limits or considered not clinically&#xD;
             significant by the investigator.&#xD;
&#xD;
          -  Screening serum urate level â‰¥ 4.5 mg/dL.&#xD;
&#xD;
          -  Subject is free of any clinically significant disease that requires a physician's care&#xD;
             and/or would interfere with study evaluations or procedures.&#xD;
&#xD;
          -  Subject has a normal or clinically acceptable physical examination.&#xD;
&#xD;
          -  Subject has no clinically relevant abnormalities in blood pressure, heart rate, and&#xD;
             body temperature, per the Investigator's judgment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive serology to human immunodeficiency virus (HIV-1 or HIV-2).&#xD;
&#xD;
          -  Positive test for active hepatitis B or hepatitis C infection.&#xD;
&#xD;
          -  History or suspicion of kidney stones.&#xD;
&#xD;
          -  Undergone major surgery within 3 months prior to Day 1.&#xD;
&#xD;
          -  Exposed to an investigational drug (or a medical device) within 30 days or 5&#xD;
             half-lives of the investigational drug (whichever is longer) prior to Day 1 or is&#xD;
             currently participating in another study of an investigational drug (or medical&#xD;
             device).&#xD;
&#xD;
          -  Prior exposure to RDEA3170.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S Baumgartner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>June 3, 2013</study_first_submitted>
  <study_first_submitted_qc>June 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verinurad</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

